Norway Genome Editing Market Size & Outlook, 2023-2030

The genome editing market in Norway is expected to reach a projected revenue of US$ 55.1 million by 2030. A compound annual growth rate of 13.9% is expected of Norway genome editing market from 2024 to 2030.
Revenue, 2023 (US$M)
$22.2
Forecast, 2030 (US$M)
$55.1
CAGR, 2024 - 2030
13.9%
Report Coverage
Norway

Norway genome editing market highlights

  • The Norway genome editing market generated a revenue of USD 22.2 million in 2023 and is expected to reach USD 55.1 million by 2030.
  • The Norway market is expected to grow at a CAGR of 13.9% from 2024 to 2030.
  • In terms of segment, (crispr)/cas9 was the largest revenue generating technology in 2023.
  • (CRISPR)/Cas9 is the most lucrative technology segment registering the fastest growth during the forecast period.


Genome editing market data book summary

Market revenue in 2023USD 22.2 million
Market revenue in 2030USD 55.1 million
Growth rate13.9% (CAGR from 2023 to 2030)
Largest segment(crispr)/cas9
Fastest growing segment(CRISPR)/Cas9
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentation(CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease
Key market players worldwideMerck KGaA, Cibus Inc Ordinary Shares - Class A, Recombinetics, Sangamo Therapeutics Inc, Editas Medicine Inc, Precision BioSciences Inc, CRISPR Therapeutics AG, Intellia Therapeutics Inc, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, AstraZeneca PLC, Takara Bio Inc, Horizon Discovery, Danaher Corp, Genscript Biotech Corp Class H, New England Biolabs, Origene Technologies, Bluebird bio Inc, Lonza Group Ltd, Thermo Fisher Scientific Inc


Other key industry trends

  • In terms of revenue, Norway accounted for 0.3% of the global genome editing market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, UK genome editing market is projected to lead the regional market in terms of revenue in 2030.
  • Italy is the fastest growing regional market in Europe and is projected to reach USD 1,597.7 million by 2030.

(crispr)/cas9 was the largest segment with a revenue share of 49.1% in 2023. Horizon Databook has segmented the Norway genome editing market based on (crispr)/cas9, talens/megatals, zfn, meganuclease covering the revenue growth of each sub-segment from 2018 to 2030.


Norway's genome editing market is growing rapidly, boosted by factors propelling innovation and investment. The country's strong scientific foundation, characterized by leading research institutions and universities, fosters a conducive environment for genetic studies.

In addition, Norway's commitment to sustainability and healthcare excellence drives interest in biotechnology, including genome editing technologies, aligning with global trends toward personalized medicine and precision therapies.

Moreover, Norway's collaborative ecosystem, which encourages partnerships among academia, industry, and government, accelerates the translation of research findings into commercial applications. Access to skilled talent, availability of venture capital, and government support further strengthen the genome editing market.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Genome Editing Market Companies

Name Profile # Employees HQ Website

Norway genome editing market size, by technology, 2018-2030 (US$M)

Norway Genome Editing Market Outlook Share, 2023 & 2030 (US$M)

Norway genome editing market size, by technology, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more